CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 432 resultados LastUpdate Última actualización 25/07/2022 [12:58:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 18 nextPage   por página


Devices and methods for treating ischaemia and acute respiratory distress syndromes

NºPublicación: AU2021218439A1 21/07/2022

Solicitante:

GALAXY CCRO INC

WO_2021163608_A2

Resumen de: AU2021218439A1

Devices and methods for conducting lateral flow immunochromatographic assays may be used, in some aspects, to measure the level of glutathione-S-transferase pi in a biological fluid collected from a human subject suspected of having had a stroke in order to determine whether the subject has had a stroke or to aid in the selection and administration of a treatment for the suspected stroke. In other aspects, such devices may be used to diagnose, monitor, and/or treat acute respiratory distress syndromes (ARDS), such as the novel coronavirus designated COVID-19.

traducir

Kit for detecting novel coronavirus, and preparation method therefor and detection method therefor

NºPublicación: AU2021351793A1 21/07/2022

Solicitante:

BEIJING JINWOFU BIOENGINEERING TECHNOLOGY CO LTD

Resumen de: AU2021351793A1

A kit for detecting novel coronavirus, and a preparation method therefor and a detection method therefor, which relate to the technical field of biomedicine. The kit comprises an antigen detection test paper, and the antigen detection test paper comprises a lining, an absorbent paper, an immune nitrocellulose membrane and an immune microsphere pad, wherein the immune microsphere pad, the immune nitrocellulose membrane and the absorbent paper are adhered to the lining. The immune microsphere pad is coated with a novel coronavirus 2019-nCoV monoclonal antibody 1 marked by latex microspheres; and the immune nitrocellulose membrane is provided with a detection line coated with a novel coronavirus 2019-nCoV monoclonal antibody 2 and a quality control line coated with a goat anti-mouse IgG polyclonal antibody. Latex particles are used as a marking tracer, and a target object is detected and analyzed by using an antigen-antibody reaction and a lateral chromatography method. The present invention has the advantages of convenience and quickness, and can be widely used in primary community hospitals and health service centers.

traducir

REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE

NºPublicación: WO2022155476A1 21/07/2022

Solicitante:

US HEALTH [US]

Resumen de: WO2022155476A1

A replication-competent adenovirus type 4 (Ad4) modified to express the SARS-CoV-2 spike protein is described. The genome of the recombinant Ad4 is modified to have a deletion of at least a portion of the adenovirus E3 region to accommodate insertion of the spike protein coding sequence. Administration of the recombinant Ad4 to the upper respiratory tract elicits mucosal immunity, which is important for protection against SARS-CoV-2 infection and for preventing transmission of the virus.

traducir

COMPOSITIONS, KITS AND METHODS FOR DIRECT AMPLIFICATION FROM CRUDE BIOLOGICAL SAMPLES

NºPublicación: WO2022155588A2 21/07/2022

Solicitante:

LIFE TECHNOLOGIES CORP [US]

Resumen de: WO2022155588A2

Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the detection of target nucleic acids, including those from microbes and/or from infectious agents such as SARS-CoV-2 and other viruses. Embodiments described herein are designed to enable processing and analysis of the sample to detect target nucleic acids within the sample without requiring extraction and/or isolation of nucleic acid from the sample prior to subsequent processing steps. Samples analyzed can thus be "crude" biological samples that do not require pre-processing prior to placement in the workflow.

traducir

VARIANT STRAIN-BASED CORONAVIRUS VACCINES

NºPublicación: WO2022155530A1 21/07/2022

Solicitante:

MODERNATX INC [US]
CARFI ANDREA
BENNETT HAMILTON
EDWARDS DARIN

Resumen de: WO2022155530A1

The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.

traducir

NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES

NºPublicación: WO2022155324A1 21/07/2022

Solicitante:

UNIV ROCKEFELLER [US]

US_2022227844_A1

Resumen de: WO2022155324A1

This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen- binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

traducir

TREATMENT OF PATHOLOGICAL FATIGUE WITH OXALOACETATE

NºPublicación: WO2022155349A1 21/07/2022

Solicitante:

CASH ALAN B [US]

Resumen de: WO2022155349A1

The present disclosure relates to methods of treatment and compositions for treatment of Pathological Fatigue caused by injury or disease in the body. Pathological fatigue refers to physical and mental fatigue that is caused by viral infection, bacterial infection, trauma, disease, or genetic alteration that results in fatigue that is not improved by bed rest and may be worsened by physical or mental activity. Such pathologic fatigue occurs in myalgic encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) and other disorders such as such as post-COVID-19 fatigue, post-viral fatigue, fibromyalgia (FM), cancer, Parkinson's Disease, other diseases and trauma as well as of combinations thereof. Related treatment methods and pharmaceutical compositions are also disclosed.

traducir

ANTIBODIES NEUTRALIZING SARS-COV-2

NºPublicación: WO2022153212A1 21/07/2022

Solicitante:

AXON NEUROSCIENCE SE [CY]

Resumen de: WO2022153212A1

The disclosure is directed, in part to antibodies against SARS-CoV-2 S protein and/or its RBD, compositions comprising those antibodies or nucleic acids encoding the same and methods of using the same.

traducir

DETECTION OF VIRAL PARTICLES BY AN IMMUNO-SPECIFIC-MEDIATED CO-PRECIPITATION

NºPublicación: WO2022152799A1 21/07/2022

Solicitante:

INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT [FR]
UNIV LILLE [FR]
CENTRE NAT RECH SCIENT [FR]
CENTRALE LILLE INST [FR]
CENTRE HOSPITALIER UNIV DE LILLE [FR]

Resumen de: WO2022152799A1

The present invention relates to a method for rapid detection or quantification of viral particles in a sample. This method is particularly useful for rapid test of SARS-CoV-2.

traducir

METHOD FOR MAXIMIZING CORONAVIRUS KILLING ACTIVITY OF HIGH-DENSITY LIPOPROTEINS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COVID-19

NºPublicación: WO2022154297A1 21/07/2022

Solicitante:

RAYDEL KOREA CO LTD [KR]

Resumen de: WO2022154297A1

The present invention relates to a method for maximizing the coronavirus killing activity of high-density lipoproteins, and a pharmaceutical composition for preventing or treating COVID-19. As identified by the present inventors, non-glycated normal high-density lipoproteins (HDLs) exhibit killing activity against coronavirus (SARS-Cov-2) that is superior to that of glycated HDLs, and thus a pharmaceutical composition for preventing and treating COVID-19, containing non-glycated normal HDLs as an active ingredient, is provided. In addition, the present invention is useful since a method for maximizing the coronavirus killing activity by using an HDL glycation inhibitor, on the basis of the identification by the present inventors, can be provided and a method for screening for a pharmaceutical composition for preventing and treating COVID-19 by evaluating the degree of HDL glycosylation inhibition of candidate drugs can be provided.

traducir

FOLD-FORMING AND COLLAPSING DEVICE AND MASK PRODUCTION MACHINE

NºPublicación: WO2022151197A1 21/07/2022

Solicitante:

ESD TECH CONSULTING & LICENSING CO LTD [CN]

Resumen de: WO2022151197A1

A fold-forming and collapsing device and a mask production machine. The fold-forming and collapsing device includes a feeding component (100) for feeding a continuous sheet material, a pre-fold forming component (200) for forming an initial sine wave-like sheet from the continuous sheet material, a primary fold forming component (300) for forming a primary sine wave-like sheet from the initial sine wave-like sheet, a fold forming and collapsing component (400) for forming mask sheet with folds from the primary sine wave-like sheet, and a receiving component (600) for receiving the mask sheet with folds. The device has achieved a better means to produce a more cost-effective and less particles-contaminated face mask with better cleanliness for use by the public in the current Covid-19 pandemic facing the global population.

traducir

TRANSMUCOSAL DOSAGE FORMS OF BREXANOLONE

NºPublicación: WO2022155507A1 21/07/2022

Solicitante:

JUBILANT PHARMA HOLDINGS INC [US]

Resumen de: WO2022155507A1

The present invention relates to sublingual pharmaceutical compositions comprising brexanolone and the process for preparing such compositions. Compositions prepared as per the present invention increase bioavailability by avoiding first-pass metabolism. The compositions of brexanolone proposed as per the present invention are useful in the treatment of depression including postpartum depression (PPD), COVID-19 infection, and other diseases.

traducir

A TRANS-COMPLEMENTATION SYSTEM FOR SARS-COV-2

NºPublicación: WO2022155521A1 21/07/2022

Solicitante:

UNIV TEXAS [US]

Resumen de: WO2022155521A1

Certain embodiments are directed to a trans-complementation system, system components, and method of using the same for SARS-CoV-2 that can be performed at BSL-2 laboratories for COVID-19 research and countermeasure development. The system thus can be used by researchers in industry, academia, and government laboratories who lack access to BSL-3 facility. This approach also can be applied to other coronaviruses.

traducir

CYTOLYTIC T CELL IMMUNOTHERAPY FOR HIGHLY PATHOGENIC CORONAVIRUSES

NºPublicación: WO2022155417A2 21/07/2022

Solicitante:

VISCIDI RAPHAEL PAUL [US]
PIVEN CHARLES J [US]

Resumen de: WO2022155417A2

Compositions and methods to induce cytolytic T lymphocytes (CD8+) response, that is, MHC class I restricted T cell responses, to pathogenic and common cold coronaviruses, including a delivery platform for antigens consisting of a polyionic papillomavirus virus-like particle (VLP), with contiguous, negatively charged amino acids flanked by a cysteine residue inserted in the HI loop of the papillomavirus L1 protein. Antigens to be paired with the VLP include fusion peptide/proteins derived from a pathogenic coronavirus, and from the genetically most closely related human coronaviruses that commonly circulate in human populations, with N-terminal or C-terminal amino acids consisting of contiguous, positively charged amino acids preceded and/or followed by a cysteine residue and a C-terminal proteolytic processing sequence (AAYY) to enhance presentation of MHC class I epitopes.

traducir

ANTI-VIRAL AGENT USED IN UPPER RESPIRATORY TRACT VIRAL INFECTIONS AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

NºPublicación: WO2022154772A1 21/07/2022

Solicitante:

ALMEDIKO SAGLIK URUNLERI TURIZM GIDA SANAYI VE TICARET LTD SIRKETI [TR]

Resumen de: WO2022154772A1

The present invention relates to an anti-viral agent for the treatment and prophylaxis of upper respiratory tract infections caused by viral (Rhinoviruses, Coronaviruses including Covid-19, Respiratory syncytial virus (RSV), Adenoviruses, Influenza and Parainfluenza viruses, Enteroviruses, Herpes simplex viruses, Cytomegaloviruses, etc.) and pharmaceutical compositions comprising the same. The effects of the developed anti-viral agent and pharmaceutical compositions comprising the same on symptoms as well as treatment and prophylaxis functions thereof have been explained. This pharmaceutical composition comprises Rosa canina L. extract, Hibiscus sabdariffa extract, Thymbra spicata L. extract, Helichrysum sp. extract, sodium alginate, glycerol, xanthan gum, steviol glycosides, raspberry flavor, mint flavor, and deionized water in a colored glass bottle or colored plastic bottle.

traducir

THE FIBER RING LOOP DAMPING SPECTROSCOPY FIBER OPTIC SENSOR AND APPLICATION METHOD OF THE SENSOR FOR DIAGNOSIS OF SARS-COV-2 VIRUS FROM BREATH

NºPublicación: WO2022154771A1 21/07/2022

Solicitante:

ESKISEHIR OSMANGAZI UNIV [TR]
ORTA DOGU TEKNIK UNIV [TR]

Resumen de: WO2022154771A1

This invention relates to the very rapid detection of SARS-CoV-2 virus, which causes COVID-19 disease, from breath using fiber optic sensors to which ultra-high sensitivity fiber ring loop damping spectroscopy (FHDSS) technique is applied. The invention is based on the application of fiber ring loop damping spectroscopy fiber optic sensor and sensor for the diagnosis of SARS-COV-2 virus from breath by collecting human breaths with breath collection bags and transporting them to the laboratory environment, which includes a sensor device for spectroscopic measurement, or by transporting the portable FRLDS fiber optic sensor system to the patient environment. Method, and its feature is that it consists of the following process steps: Preparation of the aminosilane reagent solution using acetone and keeping the sensor head (6) in this solution (200), Amine sililated sensor head (6), attaching SARS-CoV-2 IgG antibody to its surface (300), is the testing of breath samples from COVID-19 patients by sending them to the FRLDS (400) system with the SARS-CoV-2 IgG antibody attached sensor head (6).

traducir

STANDARD NUCLEIC ACID OPTIMIZED FOR USE IN RT-QPCR FOR DETECTING AND/OR QUANTIFYING SARS-COV-2, PRIMER PAIR AND PROBE

NºPublicación: WO2022153766A1 21/07/2022

Solicitante:

AIST [JP]

Resumen de: WO2022153766A1

Provided are: a standard nucleic acid optimized for use in RT-qPCR for detecting and/or quantifying SARS-CoV-2, said standard nucleic acid containing an oligonucleotide that comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1 to 5 or a complementary sequence thereof; and a set of a primer pair and a probe for specifically detecting the standard nucleic acid.

traducir

ANTIVIRAL ANTIBODY AGAINST SARS-COV2 BINDING TO ACE2, AND USE THEREOF

NºPublicación: WO2022154267A2 21/07/2022

Solicitante:

DAEGU GYEONGBUK INST SCIENCE & TECH [KR]

Resumen de: WO2022154267A2

The present invention relates to an antiviral antibody against SARS-CoV2 binding to ACE2 and a use thereof. The objective of the present invention is to prepare an antibody which binds to hACE2, and confirm that the antibody exhibits an antiviral effect against SARS-CoV2 by verifying that each antibody inhibits SARS-CoV2 virus entry into cells, thereby providing a composition comprising the antibody as a pharmaceutical composition for preventing or treating infection caused by SARS-CoV2.

traducir

NOVEL CORONAVIRUS INFECTION INHIBITING AGENT

NºPublicación: WO2022153573A1 21/07/2022

Solicitante:

RILIS CO LTD [JP]

WO_2022153572_A1

Resumen de: WO2022153573A1

[Problem] The present invention addresses the problem of providing a response to the non-existence of infection preventing agents and infection inhibiting agents that are effective against a novel coronavirus. [Solution] The present invention is obtained from, as a main material, a mixture of a persimmon fruit juice, water, and an alkaline solution. [Effect] According to the present invention, it was possible to lower the infectivity titer of a novel coronavirus by about 1/10000.

traducir

PROCESS THAT ACTS AGAINST SARS-COV-2 AND COVID-19 THROUGH EXTREMELY LOW-FREQUENCY SEQUENCES

NºPublicación: WO2022150896A1 21/07/2022

Solicitante:

DANTAS JUNIOR LUZO [BR]

Resumen de: WO2022150896A1

The present invention relates to a process that acts on SARS-CoV-2 proteins and RNA through the transmission of extremely low-frequency sequences that will act on certain amino acid and/or nucleotide sequences of the virus that causes COVID-19 or host cell receptors. The intended effect is achieved by strengthening or weakening the bonds between the chemical elements that make up nucleotides and amino acids.

traducir

PHARMACEUTICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2

NºPublicación: US2022226466A1 21/07/2022

Solicitante:

FEDERAL STATE BUDGETARY INSTITUTION NATIONAL RES CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAME [RU]

CN_114728055_PA

Resumen de: US2022226466A1

The invention relates to biotechnology. The claimed agent can be used for the prevention of SARS-CoV-2.A pharmaceutical agent may contain component (1), and contains a recombinant human adenovirus serotype genome (26), with an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and also contains component (2), comprising an agent selected from (i) a recombinant human adenovirus serotype genome (5), with an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; or (ii) a recombinant simian adenovirus serotype genome (25), with an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, or SEQ ID NO: 3.Furthermore, a pharmaceutical agent may contain component (1), comprising an agent comprising a recombinant simian adenovirus serotype genome (25), with an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, or SEQ ID NO: 3, and also contains component (2), comprising an agent comprising a recombinant human adenovirus serotype genome (5), with an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

traducir

COVID-19 Treatment

NºPublicación: US2022226414A1 21/07/2022

Solicitante:

AMIN FIRMAN ZULKIFLI [ID]
SARI MILA KURNIA [ID]

Resumen de: US2022226414A1

The disease due to infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) referred to as Coronavirus disease 2019 (COVID-19) can be treated by using a product in the form of Semen Nigella Sativa Oil (oil from Habbatus sauda seed or black cumin seed) as an ingredient or drug for COVID-19 treatment that is taken orally. The consumption is carried out daily, three times a day, with each consumption the composition of the oil content of the black cumin seeds is composed of about 450 mg, according to weight, until recovered from COVID-19.

traducir

COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTION

NºPublicación: US2022226363A1 21/07/2022

Solicitante:

UNIV YALE [US]

Resumen de: US2022226363A1

The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5′-triphosphate and/or at least one 5′-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in an immune-compromised and/or immunodeficient subject.

traducir

FAST-ACTING ANTIMICROBIAL SURFACES, AND METHODS OF MAKING AND USING THE SAME

NºPublicación: US2022225608A1 21/07/2022

Solicitante:

HRL LAB LLC [US]

WO_2021252007_A1

Resumen de: US2022225608A1

An antimicrobial coating is disclosed that provides fast transport rates of biocides for better effectiveness to deactivate SARS-CoV-2 and other viruses or bacteria on common surfaces. Some variations provide an antimicrobial structure comprising: a solid structural phase comprising a solid structural material; a continuous transport phase that is interspersed within the solid structural phase, wherein the continuous transport phase comprises a solid transport material; and an antimicrobial agent contained within the continuous transport phase, wherein the solid structural phase and the continuous transport phase are separated by an average phase-separation length from about 100 nanometers to about 500 microns. The antimicrobial structure is capable of destroying at least 99.99% of bacteria and/or viruses in 10 minutes of contact. Many options are disclosed for suitable materials to form the solid structural phase, the continuous transport phase, and the antimicrobial agent.

traducir

PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT

Nº publicación: US2022227776A1 21/07/2022

Solicitante:

COPYCAT SCIENCES INC [US]

Resumen de: US2022227776A1

The present invention provides novel compounds and pharmaceutically acceptable salts or esters thereof. For example, the compound has the structure of Formula V. Also provided is a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier. Further provided a method for inhibiting a polymerase of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2 polymerase) or treating viral infection in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition to the subject, for example, orally.

traducir

Página1 de 18 nextPage por página

punteroimgVolver